awmsg logo



pegvisomant (Somavert®)


Reference No. 3545

Publication date:
29/11/2017


Appraisal information

pegvisomant (Somavert®) 10 mg powder and solvent for solution for injection
pegvisomant (Somavert®) 15 mg powder and solvent for solution for injection
pegvisomant (Somavert®) 20 mg powder and solvent for solution for injection
pegvisomant (Somavert®) 25 mg powder and solvent for solution for injection
pegvisomant (Somavert®) 30 mg powder and solvent for solution for injection


Company: Pfizer Ltd
BNF category: Endocrine system
NMG meeting date: 04/10/2017
AWMSG meeting date: 08/11/2017
   
   
Submission Type: Resubmission
Status: Recommended
Advice No: 2417
Ministerial ratification: 28/11/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Pegvisomant (Somavert®) is recommended as an option for use within NHS Wales for the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise insulin-like growth factor-1 (IGF-1) concentrations or was not tolerated. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download
Final Appraisal Recommendation (FAR)
Download